Targeting the root cells of acute myeloid leukemia
Targeting leukemic stem cells in acute myeloid leukemia
This study is looking for new ways to treat acute myeloid leukemia (AML) by targeting the stubborn cells that help the cancer come back, with the goal of making treatments more effective for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10987026 on NIH RePORTER |
What this research studies
This research focuses on acute myeloid leukemia (AML), a type of blood cancer that is sustained by a small group of cells known as leukemia stem cells (LSCs). These LSCs are resistant to current treatments and are responsible for relapses in patients. The researchers aim to develop new therapies that specifically target the unique characteristics of LSCs, utilizing a novel approach that involves inducing bioenergetic stress to trigger differentiation and cell cycle arrest in these cells. By understanding how to effectively eliminate LSCs, the research hopes to improve treatment outcomes for AML patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with acute myeloid leukemia who have not responded well to existing treatments.
Not a fit: Patients with other types of leukemia or those who have already achieved remission from acute myeloid leukemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for acute myeloid leukemia, potentially reducing relapses and improving survival rates.
How similar studies have performed: While targeting leukemia stem cells is a relatively novel approach, preliminary studies have shown promise in similar strategies, indicating potential for success.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Qu, Cheng-Kui — Emory University
- Study coordinator: Qu, Cheng-Kui
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.